18.96
price up icon4.06%   0.74
after-market Handel nachbörslich: 18.96
loading
Schlusskurs vom Vortag:
$18.22
Offen:
$18.09
24-Stunden-Volumen:
1.23M
Relative Volume:
1.37
Marktkapitalisierung:
$2.45B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-8.8186
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+3.44%
1M Leistung:
+0.16%
6M Leistung:
-26.96%
1J Leistung:
-6.60%
1-Tages-Spanne:
Value
$18.07
$19.13
1-Wochen-Bereich:
Value
$17.91
$19.13
52-Wochen-Spanne:
Value
$14.06
$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name
Firmenname
Newamsterdam Pharma Company Nv
Name
Telefon
35 206 2971
Name
Adresse
GOOIMEER 2-35, NARRDEN
Name
Mitarbeiter
77
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
NAMS's Discussions on Twitter

Vergleichen Sie NAMS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NAMS
Newamsterdam Pharma Company Nv
18.96 2.45B 14.09M -176.94M -141.24M -2.15
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-10 Eingeleitet Stifel Buy
2025-06-04 Eingeleitet Cantor Fitzgerald Overweight
2024-12-30 Eingeleitet H.C. Wainwright Buy
2024-05-15 Eingeleitet TD Cowen Buy
2024-03-14 Eingeleitet Scotiabank Sector Outperform
2024-01-18 Eingeleitet Guggenheim Buy
2024-01-16 Eingeleitet Piper Sandler Overweight
2023-10-30 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten

pulisher
Jun 18, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World

Jun 18, 2025
pulisher
Jun 18, 2025

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria

Jun 18, 2025
pulisher
Jun 17, 2025

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 15, 2025

How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 14, 2025

Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Brokers Set Expectations for NAMS FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media

Jun 11, 2025
pulisher
Jun 11, 2025

(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 10, 2025

NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st

Jun 10, 2025
pulisher
Jun 10, 2025

Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target - marketscreener.com

Jun 10, 2025
pulisher
Jun 09, 2025

Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Pos - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Stifel initiates NewAmsterdam stock with Buy rating, $44 target - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data fr - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Says Obicetrapib Shows 'Significant' Reduction in Alzheimer's Biomarker; Shares Rise - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam reports Alzheimer’s biomarker reduction - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Pharma Reveals Positive Topline Data From BROADWAY Clinical Trial - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam reports Alzheimer’s biomarker reduction By Investing.com - Investing.com India

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

NewAmsterdam Pharma Company N.V. Announces Positive Topline Alzheimer's Disease Data from Br Broadway Clinical Trial - marketscreener.com

Jun 09, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Grows Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

NewAmsterdam Pharma Approves Key Proposals at AGM - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

NewAmsterdam Pharma to Host R&D Day on June 11, 2025 - GlobeNewswire

Jun 06, 2025
pulisher
Jun 05, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Cantor Fitzgerald - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

NewAmsterdam Pharma R&D Day: Key Pipeline Updates Coming for Revolutionary Cardiovascular Treatments - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Canto - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock By Investing.com - Investing.com India

Jun 04, 2025
pulisher
Jun 04, 2025

Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com

Jun 03, 2025

Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Newamsterdam Pharma Company Nv-Aktie (NAMS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Topper James N
Director
Jun 25 '25
Buy
18.26
1,260
23,012
3,026,133
Kling Douglas F
Chief Operating Officer
Jun 16 '25
Option Exercise
10.20
100,000
1,019,709
144,000
Kling Douglas F
Chief Operating Officer
Jun 16 '25
Sale
19.29
100,000
1,929,141
44,000
Topper James N
Director
Jun 16 '25
Buy
19.50
8,584
167,381
3,022,153
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):